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In this study, we assessed the genetic integrity of over 400 samples of human multipotent stem cells using
gene expression data sets. Our analysis reveals that neural and mesenchymal stem cells acquire character-
istic large chromosomal aberrations at a similar, or somewhat lower, frequency to that seen in pluripotent
stem cells, sometimes within a few passages in culture. Some of the identified chromosomal abnormalities
can also be detected in human tumors of the respective tissues.Human embryonic stem cells (hESCs)
acquire chromosomal aberrations in cul-
ture, in a process known as culture adap-
tation (Baker et al., 2007; Mayshar et al.,
2010). These aberrations may increase
the tumorigenicity of the cells (reviewed
in Ben-David and Benvenisty, 2011) and
disrupt their differentiation capacity (Har-
rison et al., 2007). While they are assumed
to be acquired stochastically, specific
aberrations provide selective advantage,
and are thus detected at a much higher
frequency than others. Recently, chromo-
somal aberrations were also documented
in human induced pluripotent stem cells
(hiPSCs) (Hussein et al., 2011; Laurent
et al., 2011; Mayshar et al., 2010).
While chromosomal aberrations in
pluripotent stem cells (PSCs) have been
extensively studied and characterized
(Baker et al., 2007; Hussein et al., 2011;
Laurent et al., 2011; Mayshar et al., 2010),
the phenomenon of culture adaptation in
human multipotent stem cells is much
less explored. Individual cases of chromo-
somal aberrations have been detected
in both human neural stem cells (NSCs)
(Sareen et al., 2009) and human mesen-
chymal stem cells (MSCs) (Buyanovskaya
et al., 2009; Takeuchi et al., 2009), but no
comprehensive study of the genomic sta-
bility of multipotent stem cells has been
carried out to date. Furthermore, even in
cases where the chromosomal integrity of
human multipotent stem cells was docu-
mented, such analyses were mostly per-
formed at early passages of their growth.
Thus, multipotent stem cells, as opposed
to PSCs, are generally considered to be
genetically stable (Bernardo et al., 2007;De Filippis et al., 2007; Meza-Zepeda
et al., 2008; Villa et al., 2004), and are
currently used in clinical trials in humans.
We recently developed a method for
detecting chromosomal aberrations in hu-
man PSCs, based on the gene expression
patterns of these cell lines (Mayshar et al.,
2010). Here, we expanded our analysis of
human PSCs, and in addition applied the
samemethodology to carry out a compre-
hensive analysis of large chromosomal
aberrations in 144 samples of MSCs,
97 samples of NSCs, and 177 samples
of hematopoietic stem/progenitor cells
(HSPCs), from 45 independent studies
(Figure 1A). We focused on the analysis
of the genomic integrity of whole chro-
mosomes or chromosome arms. Only
aberrations that met the stringent criteria
for statistical significance in both of
the bioinformatic tools applied are pre-
sented and discussed (see Supplemental
Experimental Procedures).
Analysis of Large Chromosomal
Aberrations in PSCs
We initially completed a comprehensive
analysis of chromosomal aberrations in
PSCs. Formerly, we identified three
sources for chromosomal aberrations in
hiPSCs: aberrations of somatic origin,
aberrations that occur during reprogram-
ming, and aberrations acquired in culture
(Mayshar et al., 2010). Here, we greatly
expanded our published analysis of the
PSC data sets, studying 39 additional
hESC samples and 65 additional hiPSC
samples from 13 recent studies (see
Table S1). Although the most common
autosomal aberrations in hESCs are tri-Cell Stem Cesomies 12 and 17 (Baker et al., 2007;May-
shar et al., 2010), previous studies failed
to detect trisomy 17 in hiPSCs, and sug-
gested this might be a difference between
these cell types (Mayshar et al., 2010;
Taapken et al., 2011). In the current anal-
ysis of PSCs, we detected further cases
of previously described aberrations (Fig-
ure 1B), and identified trisomy 17 in
hiPSCs in cell lines generated through re-
programming with synthetic mRNA mole-
cules (Figure 1C). Because this trisomy
was not identified in the parental somatic
cell line (Warren et al., 2010), and because
it appeared in culture at an early passage
of the hiPSCs, it appears to be an example
of a genomic aberration arising through
selective pressure during or immediately
following the reprogramming process.
This finding also supports the notion that
hiPSCs are prone to chromosomal aber-
rations regardless of the reprogramming
method used (Ben-David and Benvenisty,
2011; Ben-David et al., 2010), becausewe
previously identified aberrations in cell
lines reprogrammed with integrating vi-
ruses, episomal vectors, and recombinant
proteins. An ideogram of the chromo-
somal aberrations identified in PSCs is
presented as Figure 2A, and a full analysis
of the aberrations detected can be found
in Table S1. Large chromosomal aberra-
tions were identified in 9% of all the
samples analyzed, consistent with our
previous report (Mayshar et al., 2010).
Analysis of Large Chromosomal
Aberrations in Adult Stem Cells
Chromosomal aberrations are known to
accumulate in various cell types in culture.ll 9, August 5, 2011 ª2011 Elsevier Inc. 97
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SynthesisHowever, their accumulation in cultures of
adult stem cells is still a matter of open
debate. Although previous studies have
identified chromosomal aberrations in
cultured human MSCs (Røsland et al.,
2009; Ueyama et al., 2011), these reports
analyzed a rather small number of MSC
lines from bone marrow origin only, and
were thus limited in their ability to detect
recurrent chromosomal aberrations in
various types of MSCs. Other studies re-
ported that human MSCs retained chro-
mosomal stability following long-term cul-
ture in vitro (Bernardo et al., 2007; Zhang
et al., 2007). Here we analyzed published
expression profiles for MSCs from five
distinct origins. The MSC data set con-
sisted of 135 human MSC samples and
9 hESC-derived MSCs, all from 22 inde-
pendent studies. Because human MSCs
from various sources (such as bone mar-
row, adipose, and umbilical cord) clus-
tered together with each other and with
hESC-derived MSCs in an unsupervised
hierarchical clustering (Figure 1A), all the
MSC types could be analyzed using a
single common baseline. The analysis de-
tected two monosomies of chromosome
13 (from two independent studies), as
well as four monosomies of chromosome
6q (from two independent studies) (Fig-
ures 1D, 2B, and S1A). None of these
aberrations was reported in the respec-
tive original study. Our analysis also iden-
tified one line that acquired gains of chro-
mosomes 7q and 17q (Figure 1E) and one
line that acquired trisomy 19 (Figure S1B).
The latter aberrations have not been pre-
viously identified in MSCs. An ideogram
of the chromosomal aberrations identified
in MSCs is presented as Figure 2B, and
a full analysis of the detected aberrations
can be found in Table S1. Overall, we
report a frequency of aberrations of
4% for MSCs, which could possiblyFigure 1. Gene Expression Patterns Reveal Ch
(A) Unsupervised hierarchical clustering of theMSCs (g
current study (Affymetrix HG-U133plus2 platform). The
origins of the samples inside each stem cell group are
(B–G) Moving average plots of gene expression levels
hESC line, hES-T3, cultured in various conditions, dem
different studies (hESC_HD83_p24 and hESC HS235
dH1F_RiPS_1.6, demonstrate trisomy of 17q (red lin
(D) Fetal liver-derived MSC line, Liver_1, demonstrate
controls (blue lines). (E) Bone marrow-derived MSC li
passage 9 (three replicates, blue lines), the trisomy is
(three replicates, red lines, p = 2 3 e7 and p = 1 3 e
trisomy 7 (red line, p = 23 e8). This trisomywas previo
(blue line). (G) Fetal-derived NSC line acquired trisom
acquired the trisomy by passage 19 (red line, p = 1 3
See also Figure S1 and Table S1.account for the failure of previous smaller
studies to detect them.
The NSC data set comprised 58 human
NSC samples and 39 hESC-derived NSC
samples, all from 11 independent studies.
The analysis identified a trisomy of chro-
mosome 7 (Figure 1F) and recurrent cases
of trisomy 19 (Figures 2C and S1C), aber-
rations that have been previously de-
scribed to occur in NSCs (Sareen et al.,
2009). One of the detected aberrations
had been reported in the original study
(Sareen et al., 2009), while the others
had not. The analysis of the NSCs also re-
vealed a trisomy and a monosomy of
chromosome 18 (Figures 1G and 2C)
and a trisomy of chromosome 10 (Fig-
ure 2C), which had not been previously re-
ported in NSCs. The analysis of the hESC-
derived NSCs also revealed a trisomy of
chromosome 20q, which had not been
previously identified in NSCs (Figure 2c).
Because trisomy 20q is a common aber-
ration in hESCs (Lefort et al., 2008; Spits
et al., 2008), this aberration probably
arose prior to the differentiation of the
hESCs. Thus, not surprisingly, hESC-
derived NSCs seem to be susceptible to
both the typical PSC aberrations and the
typical NSC aberrations. The nature of
the acquired aberrations in each cell line
would probably depend on the time it
spent in culture in each of these states.
An ideogram of the chromosomal aberra-
tions identified in NSCs is presented as
Figure 2C, and a full analysis of the
detected aberrations can be found in
Table S1. Overall, we report a frequency
of aberrations of 9% for NSCs, a similar
frequency to the one observed for PSCs.
Finally, we analyzed a data set of 177
CD34+ HSPC samples from 12 indepen-
dent studies. Of these, 55 samples were
from healthy individuals, and 122 were
from karyotyped myeloid dysplasia syn-romosomal Aberrations in Human Stem Cells
reen branches), NSCs (blue branches), HSPCs (purple
distinct groups of stem cells cluster apart from each ot
color-coded.
along the whole genome of PSCs (B and C), MSCs (D
onstrate trisomy of chromosome 12 in this cell line (re
) are presented as controls (blue lines). (C) Synthetic
es, p = 6 3 e26). Fourteen other samples from the s
s monosomy 13 (red line, p = 3 3 e10). Six other MS
ne, #4F1560, acquired trisomies of 7q and 17q during
already evident at passage 21 (two replicates, orange
7 for trisomies 7q and 17q, respectively). (F) Fetal cor
usly identified in this cell line. The diploid NSC line from
y 18 during its passaging in culture. The cells were n
e9).
Cell Stem Cedrome (MDS) patients that we could use
as controls (Pellagatti et al., 2010). Be-
cause CD34+ samples from various sour-
ces (bone marrow, peripheral blood, and
umbilical cord blood) clustered together
with each other and with samples from
MDS patients in an unsupervised hierar-
chical clustering (Figure 1A), all the
HSPC types could be readily analyzed
using a single common baseline. Our
analysis correctly detected 34 out of the
36 reported aberrations in the patient-
derived HSPCs (the remaining two were
identified by only one of the bioinformatic
tests). A full analysis of the detected aber-
rations can be found in Table S1, and an
example is shown in Figure S1D. In con-
trast to the other stem cells analyzed,
and to the HSPCs derived from MDS
patients, we could not detect any aberra-
tion in the 55 samples of healthy donor-
derived HSPCs. Unlike NSCs and MSCs,
HSPCs are not routinely propagated
in vitro for multiple passages. Hence,
the absence of aberrations in these cells
does not necessarily suggest that they
are less susceptible to chromosomal ab-
errations in comparison with other multi-
potent stem cells; rather, it suggests that
adult stem cells are generally euploid
in vivo, and may acquire large chromo-
somal aberrations upon in vitro adapta-
tion to culture.
The Frequency, Rapidity,
and Specificity of the Acquisition
of Chromosomal Aberrations
A comparison of the frequency of chro-
mosomal aberrations in the different
types of stem cells reveals a rather similar
frequency of aberrations in all the stem
cell types that are propagated in culture:
24 aberrations in 19 out of 208 sam-
ples (9%) in PSCs, 9 aberrations in
9 out of 97 samples (9%) in NSCs, andbranches), and PSCs (red branches) analyzed in the
her, andwere thus analyzed separately. The various
and E), and NSCs (F and G). (B) Six samples of the
d lines, p = 5 3 e39). Two normal hESC lines from
mRNA-induced hiPSC lines, dH1F_RiPS_1.3 and
ame study are presented as controls (blue lines).
C samples from the same study are presented as
its passaging in culture. The cells were normal at
lines), and it took over the culture by passage 28
tex-derived NSC line, M031 CTX +7, demonstrates
the same study, M031CTX, is presented as control
ormal at passage 9 (two replicates, blue lines), but
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Figure 2. Different Types of Stem Cells Acquire Distinct Chromosomal Aberrations
(A–C) Ideograms representing the chromosomal aberrations identified in (A) PSCs, (B) MSCs, and (C) NSCs. Bars to the right of the chromosome represent gains,
and bars to the left of the chromosome represent deletions. In the ideogram of PSCs (A), red and orange represent hESCs and hiPSCs, respectively. The PSC
aberrations identified in the current study are shown together with the aberrations previously identified by Mayshar et al. (2010). Chromosomal aberrations in
samples from similar cells from the same study are interconnected by a line, and were considered as a single aberration for the purpose of statistical analysis.
(D–F) Some of the recurrent aberrations detected in stem cells are the most common aberrations in tumors of the same tissue origin. The frequency of chromo-
somal aberrations in various types of tumors was calculated using the National Cancer Institute ‘‘Recurrent Chromosomal Aberrations in Cancer Database
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Synthesis9 aberrations in 6 out of 144 samples
(4%) in MSCs. Thus, based on the data
set we have analyzed, it seems that NSCs
acquire large chromosomal aberrations
at a similar frequency to that seen in
PSCs, while MSCs acquire large chromo-
somal aberrations at a somewhat lower
frequency.
The chromosomal aberrations are not
uniformly distributed among the chromo-
somes (p = 0.043, Chi-square goodness-
of-fit test), and the specific aberrations
a cell line is likely to acquire depend on
the stem cell group to which it belongs
(p = 0.007, Fisher’s exact test). While
PSCs and NSCs tend to acquire trisomies
(100% and 89% of the aberrations, re-
spectively), MSCs tend to acquire mono-
somies (67% of the aberrations, p =
0.012, Fisher’s exact test), in line with pre-
vious reports (Buyanovskaya et al., 2009).
Most of the identified aberrations are
recurrent in a specific cell type, such as
trisomy 12 for PSCs, monosomies 6q
and 13 for MSCs, and trisomy 19 for
NSCs. Moreover, multipotent stem cells
that are derived from PCSs also harbor
the risk of acquiring the typical chromo-
somal aberrations of PSCs (such as tri-
somy 20), probably during their pluripo-
tent stage in culture. Taken together,
these data demonstrate that chromoso-
mal aberrations are a common feature
of stem cells propagated in vitro, and
further suggest that each type of stem
cell is prone to acquire a unique set of
chromosomal aberrations (illustrated in
Figure S2).
It is important to stress that the frequen-
cies of the aberrations identified in this
study refer only to aberrations that en-
compass whole chromosomes or chro-
mosome arms, and thus constitute an
underestimation of the possible total
number of genomic abnormalities in adult
stem cells. Recent studies have revealed
small copy number variations (CNVs) and
coding mutations in hiPSCs, some of
which were shown to exist in the fibro-
blasts of origin and were selected forSearcher.’’ (D) The relative frequency of trisomies, gain
the most common aberration in mature and immature
ovary (11/87). (E) The relative frequency ofmonosomie
most frequent aberration in lipomas (36/88), skeletal o
(F) The relative frequency of trisomies, gains, and isoch
astrocytomas (256/1107), and is also frequently found
common aberration in medulloblastomas. Arrows ind
tumors of the same tissue, revealing a possible corre
for MSCs and mesenchymal tumors, and marginal for
See also Figure S2 and Table S1.during reprogramming, while others arose
de novo during this process or after the
growth of the cells in culture (Gore et al.,
2011; Hussein et al., 2011; Laurent et al.,
2011). It is therefore reasonable to assume
that CNVs and point mutations would also
arise during the culture propagation of
multipotent stem cells.
We recently reported that trisomy
12 accumulates in PSC cultures rapidly,
and could take over the culture within
as few as five passages (Mayshar et al.,
2010). In this study, two cell lines that ac-
quired chromosomal aberrations in cul-
ture were also analyzed at earlier time
points. Thus, we show that in MSCs chro-
mosomal aberrations can take over the
culture in as few as seven passages
(Figure 1E), and in NSCs, in as few as
six passages (Figure 1G). We conclude,
therefore, that multipotent stem cells are
prone to acquire advantageous chromo-
somal aberrations, which enable them to
rapidly outgrow the normal cell popula-
tion, at a similar rate as that previously re-
ported for PSCs.
An Analysis of Lineage-Specific
Chromosomal Aberrations In Vitro
and In Vivo
We next looked at the relationship be-
tween the chromosomal aberrations we
detected in stem cell cultures and those
seen in human tumors. In order to perform
an unbiased quantification of the aberra-
tions in different types of tumors, we gath-
ered data from thousands of tumors of the
same tissues as the various stem cells
analyzed, using a well-established data-
base of chromosomal aberrations in can-
cer (Mitelman et al., 2007, 2011). A calcu-
lation of the frequency of chromosomal
aberrations in these tumors revealed a
partial correlation between the lineage-
specific aberrations that arise in stem
cell cultures and the ones most common
in tumors of the respective tissue. The
association is most prominent in PSCs:
trisomy 12 is themost common aberration
in PSC cultures, and is by far the mosts, and isochromosomes of each chromosome in three
teratomas (found in 182/827 cases), seminomas of the
s and deletions of each chromosome in three types of tu
steosarcomas (49/694), and dedifferentiated chondro
romosomes in three types of neural tumors. Trisomy 7 i
in medulloblastomas (29/280). Trisomy 17, which wa
icate chromosomes that were identified in stem cell c
lation between the two (the correlation is most evide
NSCs and neural tumors).
Cell Stem Celcommon aberration in three types of
tumors of germ cell tissues (teratomas,
seminomas, and ovarian adenomas) (Fig-
ure 2D). In MSCs, two aberrations were
found to recur in independent studies;
one of them, monosomy 13, is also stron-
gly related to mesenchymal tumors, be-
cause it was found to be a frequent mono-
somy in bone and soft tissue tumors
(lipomas, as well as chondrosarcomas
and osteosarcomas) (Figure 2E). In NSCs,
the association is weaker: trisomy 19
was found to arise recurrently, but trisomy
7 is the most prevalent in various brain
tumors (gliomas, astrocytomas, and me-
dulloblastomas) (Figure 2F). Trisomy 7
was reported to recur in NSCs (Sareen
et al., 2009), but was identified only once
in the current analysis.
The associations between chromo-
somal aberrations in stem cell cultures
and in tumors of the same tissues do not
necessarily mean that stem cells that
acquired these aberrations would be
more tumorigenic; they do imply, how-
ever, that specific aberrations at least
confer growth advantage in a cell line-
age-specific manner, both to stem cells
in vitro and to tumors in vivo. If this were
true, we would expect these two phe-
nomena to share at least some of the
genes involved. Supporting this notion,
Retinoblastoma (RB1), which is located
on 13q14, was found to be downregu-
lated in many mesenchymal tumors with
chromosome 13 deletion (Dahle´n et al.,
2003; Yamaguchi et al., 1996), and was
also significantly downregulated in the
two lines detected in our analysis to
harbor monosomy 13 (2.2-fold and 5.3-
fold decrease, p = 0.015, Student’s t test).
Concluding Remarks
Transplantation of human adult stem cells
may result in tumor formation (Amariglio
et al., 2009; Casalbore et al., 2009). In
the current analysis we identified stem
cell-specific chromosomal aberrations,
and compared the frequency, the iden-
tity, and the acquisition rate of thesetypes of tumors of germ cell tissues. Trisomy 12 is
testis and the ovary (91/479), and adenomas of the
mors ofmesenchymal tissues.Monosomy 13 is the
sarcomas (9/89).
s themost common aberration in gliomas (9/43) and
s not detected in the analysis of NSCs, is the most
ultures of a specific type and are also frequent in
nt for PSCs and germ cell tumors, less significant
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stem cells. We found that (1) NSCs and
MSCs acquire large chromosomal aber-
rations in culture at a similar (for NSCs)
or somewhat lower (for MSCs) frequency
to that seen in PSCs; (2) different stem
cell types acquire distinct chromosomal
abnormalities; and (3) once these aberra-
tions occur, they take over the culture
rapidly. Thus, we conclude that, as for
pluripotent cells, the genomic stability of
multipotent stem cells in culture should
also be analyzed carefully and regularly.
Large chromosomal aberrations might
also arise in HSPCs, once the required
conditions for their routine in vitro propa-
gation are finally discovered. Chromo-
somal aberrations in PSCs have been
previously suggested to increase their
tumorigenicity (Ben-David et al., 2010);
such aberrations might affect the safety
of aberrant multipotent stem cells as
well. Thus, validating the genomic integ-
rity of stem cells of all types in culture is
crucial, both for the correct interpretation
of biological results and for their safe im-
plementation in cell therapy.
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